<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861016</url>
  </required_header>
  <id_info>
    <org_study_id>D4025L00006</org_study_id>
    <nct_id>NCT00861016</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension</brief_title>
  <official_title>An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy
      and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with
      mild to moderate essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects reaching blood pressure target at wk 8 after metoprolol succinate prolonged release tablet treatment, and magnitude of systolic and diastolic blood pressure reduction from baseline among subjects who reached target (below 140/90mmHg).</measure>
    <time_frame>Day -7— -1, Day1, Day 28, Day 56,Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The magnitude of systolic and diastolic blood pressure reduction from baseline among all the subjects at week 8 after metoprolol succinate prolonged release tablet treatment.</measure>
    <time_frame>Day -7— -1, Day1, Day 28, Day 56,Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects reaching blood pressure target at week 4, and the magnitude of systolic and diastolic blood pressure reduction from baseline among all the subjects and those subjects who reached target</measure>
    <time_frame>Day -7— -1, Day1, Day 28, Day 56,Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects reaching blood pressure target at week 12, and the magnitude of systolic and diastolic blood pressure reduction from baseline among all the subjects and those subjects who reached target</measure>
    <time_frame>Day -7— -1, Day1, Day 28, Day 56,Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with mild to moderate essential hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoprolol succinate prolonged-release tablet and felodipine</intervention_name>
    <description>a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Betaloc ZOK and Plendil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Newly diagnosed essential hypertension who have not received anti- hypertensive
             treatment, or patients without antihypertensive medication in two weeks before
             screening, 90mmHg&lt;SiDBP &lt;110mmHg and SiSBP &lt;180mmHg.

        Exclusion Criteria:

          -  Known or suspected secondary hypertension

          -  Resting HR is &lt; 55bpm.

          -  Sick sinus syndrome

          -  Atrioventricular block of first degree (with P-R&gt;0.24seconds), or second or third
             degree
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisheng Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>BeiJing Hypertension League</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>March 12, 2009</last_update_submitted>
  <last_update_submitted_qc>March 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marco Avila</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Post marketing study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Felodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

